Our Pipeline
Our programs are steadily advancing with leading programs of ET-01 for severe β-thalassemia and U CAR-T ET-02 for cancer.

Our programs are steadily advancing with leading programs of ET-01 for severe β-thalassemia and U CAR-T ET-02 for cancer.